Tech Company Financing Transactions
Ceregene Funding Round
Ceregene closed a $32 million Series B venture capital round on 8/4/2004. Backers included Alta Partners, MPM Capital and Apex Venture Partners.
Transaction Overview
Company Name
Announced On
8/4/2004
Transaction Type
Venture Equity
Amount
$32,000,000
Round
Series B
Investors
Alta Partners (Lead Investor) (David Mack)
MPM Capital (Lead Investor) (Dennis Henner)
Proceeds Purpose
Proceeds from this round of financing will be used to advance Ceregene's lead product candidates including CERE-120 for Parkinson's disease as well as CERE-130 for amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease and CERE-110 for Alzheimer's disease.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
9381 Judicial Dr. 130
San Diego, CA 92121
USA
San Diego, CA 92121
USA
Phone
Website
Email Address
Overview
Using gene therapy delivery systems, Ceregene's primary focus is the discovery and development of novel genetic therapeutics for the treatment of neurological disorders. Ceregene aims to be the leader in the field of Central Nervous System (CNS) disease treatment using molecular medicine, an area of great unmet medical need.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jeffrey Ostrove
Chief Scientific Officer
Raymond Bartus
Controller
Carolyn Bonebright
Browse more venture capital transactions:
Prev: 8/4/2004: Kalypsys venture capital transaction
Next: 8/6/2004: ReQuest Multimedia venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs